Roche's novel checkpoint inhibitor delivers mixed results in new lung cancer study

feature-image

Play all audios:

Roche on Wednesday said a two-drug combination that includes a novel but still experimental checkpoint-blocking immunotherapy significantly delayed tumor progression in a mid-stage study of


non-small cell lung cancer patients. Reaction to the results might be muted, however, because the new combination treatment — tiragolumab plus Tecentriq — only showed a meaningful benefit in


a subset of lung cancer patients. That profile makes it unlikely to compete against Merck’s dominant Keytruda-chemotherapy combination. Roche announced the full study results to coincide


with the release of a research abstract for the annual meeting of the American Society of Clinical Oncology (ASCO). STAT+ Exclusive Story Already have an account? Log in THIS ARTICLE IS


EXCLUSIVE TO STAT+ SUBSCRIBERS UNLOCK THIS ARTICLE — PLUS DAILY COVERAGE AND ANALYSIS OF THE BIOTECH SECTOR — BY SUBSCRIBING TO STAT+. Already have an account? Log in Individual plans Group


plans View All Plans To read the rest of this story subscribe to STAT+. Subscribe